2. Search Result
Search Result
Results for "

HCC

" in MedChemExpress (MCE) Product Catalog:

221

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

4

Biochemical Assay Reagents

2

Peptides

5

Inhibitory Antibodies

43

Natural
Products

11

Recombinant Proteins

5

Isotope-Labeled Compounds

2

Antibodies

1

Click Chemistry

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131045
    HADA hydrochloride
    4 Publications Verification

    HCC-Amino-D-alanine hydrochloride

    		 Bacterial Infection
    HADA hydrochloride (HCC-Amino-D-alanine hydrochloride) is a blue (λem~450 nm) fluorescent D-amino acid (FDAA). FDAAs are efficiently incorporated into the peptidoglycans (PGs) of diverse bacterial species at the sites of PG biosynthesis, allowing specific and covalent probing of bacterial growth with minimal perturbation .
    HADA hydrochloride
  • HY-RS16314
    HCC Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HCC Human Pre-designed siRNA Set A contains three designed siRNAs for HCC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HCC Human Pre-designed siRNA Set A
    HCC Human Pre-designed siRNA Set A
  • HY-RS22197
    Hccs Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hccs Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hccs gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hccs Mouse Pre-designed siRNA Set A
    Hccs Mouse Pre-designed siRNA Set A
  • HY-RS28719
    Hccs Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Hccs Rat Pre-designed siRNA Set A contains three designed siRNAs for Hccs gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Hccs Rat Pre-designed siRNA Set A
    Hccs Rat Pre-designed siRNA Set A
  • HY-RS16456
    HCCS Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HCCS Human Pre-designed siRNA Set A contains three designed siRNAs for HCCS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HCCS Human Pre-designed siRNA Set A
    HCCS Human Pre-designed siRNA Set A
  • HY-173387
    4F-Docetaxel

    4FDT

    		 Others Cancer
    4F-Docetaxel (4FDT) is a fluorinated docetaxel analog. 4F-Docetaxel has anti-hepatoma activity and can be used for research of hepatocellular carcinoma (HCC) .
    4F-Docetaxel
  • HY-168609
    CRI9

    		Apoptosis c-Met/HGFR mTOR PI3K Akt Cancer
    CRI9 inhibits the c-MET/PI3K/Akt/mTOR pathway, suppressing the growth of liver cancer cells. CRI9 shows strong cytotoxicity against HCC cells, inducing apoptosis .
    CRI9
  • HY-172394
    ZSNI-21

    		HDAC ADAMTS Cancer
    ZSNI-21 is a dual inhibitor of ADAM17 and HDAC2. ZSNI-21 effectively inhibits the proliferation of Bel-7402 cells and demonstrates significant anti-metastatic capabilities against HCC-LM3 cells. ZSNI-21 is promising for research of hepatocellular carcinoma (HCC) .
    ZSNI-21
  • HY-170690
    FGFR4-IN-22

    		FGFR Cancer
    FGFR4-IN-22 (compound 10f) is a potent inhibitor of FGFR4, with the IC50 of 5.4 nM. FGFR4-IN-22 serve as a potential lead compound targeting FGFR4 for anti-HCC agent development .
    FGFR4-IN-22
  • HY-162679
    c-Met degrader-1

    		c-Met/HGFR Apoptosis Cancer
    c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .
    c-Met degrader-1
  • HY-172885
    TRBP-IN-1

    		DNA/RNA Synthesis MicroRNA Apoptosis Pyroptosis Cancer
    TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC50: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC50: 18.96 μM); SK-Hep-1 cells (IC50: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC .
    TRBP-IN-1
  • HY-N4168B
    Methyl chlorogenate

    		Others Cancer
    Methyl chlorogenate is an antioxidant, and has radical scavenging activity. Methyl chlorogenate is an anti-inflammatory agent. Methyl chlorogenate also inhibits hepatocellular carcinoma (HCC) cell proliferation and metastasis .
    Methyl chlorogenate
  • HY-151461
    CHNQD-01255

    		Arf Family GTPase Cancer
    CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .
    CHNQD-01255
  • HY-147187
    MNK8

    		STAT Apoptosis Bcl-2 Family Survivin Cancer
    MNK8 is a potent STAT3 (signal transducer and activator of transcription 3) inhibitor. MNK8 inhibits STAT3 activation and reduced its DNA binding ability. MNK8 shows good growth inhibition against hepatocellular carcinoma (HCC) cells. MNK8 induces apoptosis in HCC cells. MNK8 reduces prosurvival proteins expression and migration/invasion of HCC cells .
    MNK8
  • HY-168085
    CV-4-26

    		YAP Apoptosis Cancer
    CV-4-26 (Compound 22) is a covalent inhibitor of TEAD. CV-4-26 inhibits YAP/TEAD-based transcription, leading to the reduction of CTGF and CYR61 expression. CV-4-26 inhibits Huh7 and HepG2 cell colony formation, induces cell cycle arrest, and apoptosis. CV-4-26 shows antitumor activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB) .
    CV-4-26
  • HY-N6623
    Malvidin-3-galactoside chloride

    		Apoptosis Endogenous Metabolite Reactive Oxygen Species Cancer
    Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .
    Malvidin-3-galactoside chloride
  • HY-164410
    MO-I-1100

    		Notch Cancer
    MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. MO-I-1100 suppresses HCC cell migration, invasion and anchorage independent growth. MO-I-1100 shows antitumor effects through inhibiting Notch signaling cascade in HCC .
    MO-I-1100
  • HY-N2591A
    Isocorydine hydrochloride

    		Endogenous Metabolite Cancer
    Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
    Isocorydine hydrochloride
  • HY-18750A
    Zorifertinib hydrochloride

    AZD3759 hydrochloride

    		 EGFR Apoptosis Cancer
    Zorifertinib (AZD3759) hydrochloride is a potent, orally active, central nervous system-penetrant, EGFR inhibitor (IC50s: 0.3, 0.2, and 0.2 nM for EGFR wt, EGFR L858R, and EGFR exon 19Del, respectively). Zorifertinib hydrochloride induces cancer cell apoptosis. Zorifertinib hydrochloride has antitumor activity, and can be used for NSCLC, HCC etc. research .
    Zorifertinib hydrochloride
  • HY-W013514
    2-Acetamidofluorene

    		DNA/RNA Synthesis Cancer
    2-Acetamidofluorene is a potent carcinogenan. 2-Acetamidofluorene is can be used fot induction of hepatocellular carcinoma (HCC) and multiple primary tumours .
    2-Acetamidofluorene
  • HY-N2858
    Alpinumisoflavone acetate

    		Apoptosis Cancer
    Alpinumisoflavone acetate is a anticancer agent. Alpinumisoflavone acetate shows antiproliferative activity. Alpinumisoflavone acetate decreases the expression of phosphorylation of ERK1/2. Alpinumisoflavone acetate induces mitochondrial dysfunction and mitochondria-mediated Apoptosis. Alpinumisoflavone acetate has the potential for the research of HCC .
    Alpinumisoflavone acetate
  • HY-149475
    VEGFR-2-IN-33

    		VEGFR Cancer
    VEGFR-2-IN-33 (Compound 4d) is a VEGFR inhibitor (IC50: 61.04 nM). VEGFR-2-IN-33 inhibits HepG2 cell proliferation with an IC50 of 4.31 nM. VEGFR-2-IN-33 can be used for research of hepatocellular carcinoma (HCC) .
    VEGFR-2-IN-33
  • HY-P99353
    Ascrinvacumab
    2 Publications Verification

    Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
    Ascrinvacumab
  • HY-144759
    FGFR4-IN-9

    		FGFR Cancer
    FGFR4-IN-9 (Compound 6O) is a selective FGFR4 inhibitor with an IC50 of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .
    FGFR4-IN-9
  • HY-120349
    LL-Z1640-4

    		p38 MAPK JNK Apoptosis Reactive Oxygen Species Cancer
    LL-Z1640-4 is a potent p38/JNK signaling inhibitor. LL-Z1640-4 significantly diminishes p38 and JNK activation in HCC cells transfected with MLK4 siRNA. LL-Z1640-4 markedly attenuates ROS production induced by MLK4 knockdown. LL-Z1640-4 significantly reduces the apoptotic cells in HCC cells transfected with siMLK4 .
    LL-Z1640-4
  • HY-N6623R
    Malvidin-3-galactoside chloride (Standard)

    		Apoptosis Endogenous Metabolite Reactive Oxygen Species Cancer
    Malvidin-3-galactoside (chloride) (Standard) is the analytical standard of Malvidin-3-galactoside (chloride). This product is intended for research and analytical applications. Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .
    Malvidin-3-galactoside chloride (Standard)
  • HY-132177
    α-L-Fucosidase, Microorganism
    1 Publications Verification

    EC 3.2.1.51; FUC

    		 Endogenous Metabolite Cancer
    α-L-Fucosidase, Microorganism (EC 3.2.1.51) is an enzyme that catalyzes the chemical reaction. Serum activity of α-L-Fucosidase, Microorganism, a lysosomal enzyme present in all mammalian cells, has been proposed as a marker of hepatocellular carcinoma (HCC) .
    α-L-Fucosidase, Microorganism
  • HY-W015309
    Decanoic acid
    2 Publications Verification

    		 iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .
    Decanoic acid
  • HY-162969
    MRTF-A-IN-2

    		Ras Cardiovascular Disease Metabolic Disease
    MRTF-A-in-2 (Compound 16) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
    MRTF-A-IN-2
  • HY-162968
    MRTF-A-IN-1

    		Ras Cardiovascular Disease Metabolic Disease
    MRTF-A-in-1 (Compound 14) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging .
    MRTF-A-IN-1
  • HY-142945
    KRAS G12C inhibitor 43

    		Ras Cancer
    KRAS G12C inhibitor 43 (compound 59) is a potent KRAS G12C inhibitor. KRAS G12C inhibitor 43 shows antimigration and anti-proliferative activity with IC50s of 0.001-1 µM, >1 µM, >1 µM for H358, A549, HCC cells ,respectively .
    KRAS G12C inhibitor 43
  • HY-W015309R
    Decanoic acid (Standard)

    		iGluR Tyrosinase c-Met/HGFR Glutaminase Neurological Disease Metabolic Disease Cancer
    Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .
    Decanoic acid (Standard)
  • HY-162259
    QC-182

    		PROTACs Histone Acetyltransferase Cancer
    QC-182 is a potent PROTAC degrader of p300/CBP. QC-182 reduces p300 protein in the SK-HEP-1 cells (DC50 = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC50 values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .
    QC-182
  • HY-P99013
    Codrituzumab
    1 Publications Verification

    GC33; RO5137382

    		 Glycoprotein VI Cancer
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
    Codrituzumab
  • HY-147918
    Anticancer agent 73

    		DNA/RNA Synthesis Cancer
    Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
    Anticancer agent 73
  • HY-130173
    Bafilomycin C1
    1 Publications Verification

    		 Bacterial Fungal Na+/K+ ATPase Apoptosis Antibiotic Infection Cancer
    Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H +-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi . Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC) .
    Bafilomycin C1
  • HY-162650
    SL44

    		ClpP Cancer
    SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg). SL44 exhibits good pharmacokinetic characters in rat models .
    SL44
  • HY-N7073
    Silymarin
    5 Publications Verification

    		 SARS-CoV Infection Neurological Disease Inflammation/Immunology Cancer
    Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
    Silymarin
  • HY-15897
    LDN-212854
    1 Publications Verification

    		 TGF-β Receptor Cancer
    LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .
    LDN-212854
  • HY-150596
    CT1-3

    		Apoptosis Bcl-2 Family JNK Cancer
    CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
    CT1-3
  • HY-15485
    Zardaverine
    1 Publications Verification

    		 Phosphodiesterase (PDE) Apoptosis Inflammation/Immunology Cancer
    Zardaverine is an orally active and selective PDE3/4 inhibitor (IC50)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma .
    Zardaverine
  • HY-19345
    Vacquinol-1

    NSC13316

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1
  • HY-19345A
    Vacquinol-1 dihydrochloride

    NSC13316 dihydrochloride

    		 p38 MAPK Cancer
    Vacquinol-1 (NSC13316) dihydrochloride is a MKK4-specific activator that activates MAPK pathways . Vacquinol-1 dihydrochloride specifically induces human glioblastoma cell (GC) death, attenuates tumor progression and prolongs survival in a glioblastoma multiforme (GBM) mouse model . Vacquinol-1 dihydrochloride also induces apoptosis in hepatocellular carcinoma (HCC)cell .
    Vacquinol-1 dihydrochloride
  • HY-152169
    BIHC

    		Interleukin Related Apoptosis TNF Receptor IFNAR NF-κB Bcl-2 Family Inflammation/Immunology
    BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD) .
    BIHC
  • HY-161617
    LASSBio-2052

    		DNA/RNA Synthesis Apoptosis Cancer
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells .
    LASSBio-2052
  • HY-172815
    IDB-001

    		DNA/RNA Synthesis Cancer
    IDB-001 is an inhibitor of ribosome PTC that inhibits protein synthesis in a sequence-selective manner. IDB-001 inhibits HCC-1143 with EC50 value of 0.84 μM. IDB-001 inhibits MYC-dependent cancer cell viability .
    IDB-001
  • HY-146423
    PROTAC EGFR degrader 6

    		PROTACs EGFR Apoptosis Cancer
    PROTAC EGFR degrader 6, a PROTAC EGFR degrader, potently degrades EGFR Del19 in HCC827 cells with the DC50 of 45.2 nM. PROTAC EGFR degrader 6 significantly induces the apoptosis of HCC827 cells and arrest the cells in G1 phase .
    PROTAC EGFR degrader 6
  • HY-119833
    Rubone

    		MicroRNA Cancer
    Rubone, a chalcone analog, is a modulator of miR-34a. Rubone upregulates miR-34a expression in a p53 dependent manner, downregulates the downstream target Bcl-2 and Cyclin D1 expression, and suppresses hepatocellular carcinoma (HCC) growth in vivo. Rubone enhances the anticancer effect of Paclitaxel (PTX; HY-B0015) in PTX-resistant prostate cancer cell lines by reversing the expression of miR-34a downstream targets .
    Rubone
  • HY-163461
    4F-DDC

    		PARP Cancer
    4F-DDC is a novel PARP1 inhibitor with an IC50 value of 82 nM. 4F-DDC induces DNA damage and activates the cGAS–STING pathway. 4F-DDC inhibits the growth of HCC-1937-derived tumor xenografts .
    4F-DDC
  • HY-146422
    PROTAC EGFR degrader 5

    		PROTACs EGFR Apoptosis Cancer
    PROTAC EGFR degrader 5 (Compound 10), a PROTAC EGFR degrader, potently degrades EGFR Del19 in HCC827 cells with the DC50 of 34.8 nM. PROTAC EGFR degrader 5 significantly induces the apoptosis of HCC827 cells and arrest the cells in G1 phase .
    PROTAC EGFR degrader 5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: